c-Met-mediated reactivation of PI3K/AKT signaling contributes to insensitivity of BRAF(V600E) mutant thyroid cancer to BRAF inhibition

PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors.

(2017) S. Kopetz et al.   JOURNAL OF CLINICAL ONCOLOGY

Diagnosis and management of differentiated thyroid cancer using molecular biology

(2013) Robert L. Witt et al.   LARYNGOSCOPE

BRAF V600E Inhibition in Anaplastic Thyroid Cancer

(2013) Michael H. Rosove et al.   NEW ENGLAND JOURNAL OF MEDICINE

Déjà Vu: EGF Receptors Drive Resistance to BRAF Inhibitors

(2013) Maria Romina Girotti et al.   Cancer Discovery

Relief of Feedback Inhibition of HER3 Transcription by RAF and MEK Inhibitors Attenuates Their Antitumor Effects in BRAF -Mutant Thyroid Carcinomas

(2013) Cristina Montero-Conde et al.   Cancer Discovery

Phase II Efficacy and Pharmacogenomic Study of Selumetinib (AZD6244; ARRY-142886) in Iodine-131 Refractory Papillary Thyroid Carcinoma with or without Follicular Elements

(2012) D. N. Hayes et al.   CLINICAL CANCER RESEARCH

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

(2012) Ravid Straussman et al.   NATURE

BRAF Inhibition in Refractory Hairy-Cell Leukemia

(2012) Sascha Dietrich et al.   NEW ENGLAND JOURNAL OF MEDICINE

EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib

(2012) Ryan B. Corcoran et al.   Cancer Discovery

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE